Tag: #Global Trends

Key Development Teva Pharmaceutical Industries has reported positive Phase 2a topline results for TEV-408, an investigational human monoclonal antibody targeting... Read more

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially approved the supplemental Biologics License Application... Read more

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) officially granted marketing approval for Bixlenvo® (bictegravir... Read more

Key Development On August 27, 2026, the U.S. Food and Drug Administration (FDA) approved Bixlenvo® (bictegravir 75 mg / lenacapavir... Read more

Key Development On August 28, 2026, the U.S. Food and Drug Administration (FDA) approved an expanded indication for Mounjaro® (tirzepatide),... Read more

Key Development At the European Society of Cardiology (ESC) Congress 2026 in Munich, AstraZeneca (LSE/STO/Nasdaq: AZN) and Ionis Pharmaceuticals (Nasdaq:... Read more

Key Development The Vietnam Food Administration (VFA) under the Ministry of Health has issued an urgent regulatory directive requesting the... Read more

Key Development On August 28, 2026, the U.S. FDA approved an expanded indication for Eli Lilly’s Mounjaro® (tirzepatide) to reduce... Read more

Key Development Genentech, a member of the Roche Group, has entered a global collaboration and licensing agreement with DualityBio to... Read more